FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1583849384> ?p ?o ?g. }

• W1583849384 endingPage "168" @default.
• W1583849384 startingPage "159" @default.
• W1583849384 abstract "<b><i>Background:</i></b> Idiopathic membranous nephropathy remains the leading cause of nephrotic syndrome in Caucasian adults. Immunosuppressive therapy with cyclosporine (CSA) is often successful in reducing proteinuria, but its use is associated with a high relapse rate. Rituximab, a monoclonal antibody that specifically targets CD20 on the surface of B-cells, is effective in achieving a complete remission of proteinuria in patients with idiopathic membranous nephropathy. However, whether rituximab is as effective as CSA in inducing and maintaining complete or partial remission of proteinuria in these patients is unknown. The membranous nephropathy trial of rituximab (MENTOR) hypothesizes that B-cell targeting with rituximab is non-inferior to CSA in inducing long-term remission of proteinuria. <b><i>Methods and Design:</i></b> Patients with idiopathic membranous nephropathy, proteinuria ≥5 g/24 h, and a minimum of 3 months of Angiotensin-II blockade will be randomized into a 12-month treatment period with IV rituximab, 1,000 mg (2 infusions, 14 days apart; repeated at 6 months if a substantial reduction in proteinuria (equal to or >25%) is seen at 6 months) or oral CSA 3.5-5 mg/kg/day for 6 months (continued for another 6 months if a substantial reduction in proteinuria (equal to or >25%) is seen at 6 months). The efficacy of treatment will be assessed by the remission status (based on changes in proteinuria) at 24 months from randomization. Patient safety will be assessed via collection of adverse event data and evaluation of pre- and posttreatment laboratory data. At the 6-month post-randomization visit, patients who have been randomized to either CSA or rituximab but who do not have a reduction in proteinuria ≥25% (confirmed on repeat measurements within 2 weeks) will be considered treatment failures and exit the study. <b><i>Discussion:</i></b> This study will test for the first time whether treatment with rituximab is non-inferior to CSA in inducing long-term remission (complete or partial) of proteinuria in patients with idiopathic membranous nephropathy." @default.
• W1583849384 created "2016-06-24" @default.
• W1583849384 creator A5000517864 @default.
• W1583849384 creator A5004311843 @default.
• W1583849384 creator A5004579061 @default.
• W1583849384 creator A5005543157 @default.
• W1583849384 creator A5009709356 @default.
• W1583849384 creator A5010304127 @default.
• W1583849384 creator A5012288468 @default.
• W1583849384 creator A5016853434 @default.
• W1583849384 creator A5020485651 @default.
• W1583849384 creator A5024974847 @default.
• W1583849384 creator A5031802922 @default.
• W1583849384 creator A5042356850 @default.
• W1583849384 creator A5044724361 @default.
• W1583849384 creator A5045290398 @default.
• W1583849384 creator A5045391884 @default.
• W1583849384 creator A5046195537 @default.
• W1583849384 creator A5048525391 @default.
• W1583849384 creator A5054993212 @default.
• W1583849384 creator A5056005907 @default.
• W1583849384 creator A5056935796 @default.
• W1583849384 creator A5057558630 @default.
• W1583849384 creator A5059150390 @default.
• W1583849384 creator A5059326014 @default.
• W1583849384 creator A5067563722 @default.
• W1583849384 creator A5070922317 @default.
• W1583849384 creator A5070946918 @default.
• W1583849384 creator A5071417113 @default.
• W1583849384 creator A5073141203 @default.
• W1583849384 creator A5073207965 @default.
• W1583849384 creator A5074148877 @default.
• W1583849384 creator A5074327597 @default.
• W1583849384 creator A5076094519 @default.
• W1583849384 creator A5081852099 @default.
• W1583849384 creator A5087456974 @default.
• W1583849384 creator A5088037254 @default.
• W1583849384 creator A5088796897 @default.
• W1583849384 date "2015-01-01" @default.
• W1583849384 modified "2023-10-13" @default.
• W1583849384 title "A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR)" @default.
• W1583849384 cites W1530168030 @default.
• W1583849384 cites W1963948820 @default.
• W1583849384 cites W1981088341 @default.
• W1583849384 cites W1991441433 @default.
• W1583849384 cites W1991878257 @default.
• W1583849384 cites W2001369234 @default.
• W1583849384 cites W2002034691 @default.
• W1583849384 cites W2010214780 @default.
• W1583849384 cites W2018459774 @default.
• W1583849384 cites W2020835189 @default.
• W1583849384 cites W2023720190 @default.
• W1583849384 cites W2028590773 @default.
• W1583849384 cites W2029988322 @default.
• W1583849384 cites W2041514348 @default.
• W1583849384 cites W2044080899 @default.
• W1583849384 cites W2047390341 @default.
• W1583849384 cites W2056846666 @default.
• W1583849384 cites W2059026853 @default.
• W1583849384 cites W2059074530 @default.
• W1583849384 cites W2070961177 @default.
• W1583849384 cites W2090021700 @default.
• W1583849384 cites W2097148864 @default.
• W1583849384 cites W2099746633 @default.
• W1583849384 cites W2105724464 @default.
• W1583849384 cites W2107002794 @default.
• W1583849384 cites W2122581834 @default.
• W1583849384 cites W2125503275 @default.
• W1583849384 cites W2127127482 @default.
• W1583849384 cites W2128089274 @default.
• W1583849384 cites W2133344401 @default.
• W1583849384 cites W2141219630 @default.
• W1583849384 cites W2144479843 @default.
• W1583849384 cites W2156121263 @default.
• W1583849384 cites W2158479143 @default.
• W1583849384 cites W2166158692 @default.
• W1583849384 cites W2166822765 @default.
• W1583849384 cites W2168217071 @default.
• W1583849384 cites W2168815834 @default.
• W1583849384 cites W3026011315 @default.
• W1583849384 doi "https://doi.org/10.1159/000430849" @default.
• W1583849384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26087670" @default.
• W1583849384 hasPublicationYear "2015" @default.
• W1583849384 type Work @default.
• W1583849384 sameAs 1583849384 @default.
• W1583849384 citedByCount "48" @default.
• W1583849384 countsByYear W15838493842015 @default.
• W1583849384 countsByYear W15838493842016 @default.
• W1583849384 countsByYear W15838493842017 @default.
• W1583849384 countsByYear W15838493842018 @default.
• W1583849384 countsByYear W15838493842019 @default.
• W1583849384 countsByYear W15838493842021 @default.
• W1583849384 countsByYear W15838493842022 @default.
• W1583849384 countsByYear W15838493842023 @default.
• W1583849384 crossrefType "journal-article" @default.
• W1583849384 hasAuthorship W1583849384A5000517864 @default.
• W1583849384 hasAuthorship W1583849384A5004311843 @default.
• W1583849384 hasAuthorship W1583849384A5004579061 @default.

• next